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Significance: Cutaneous wound healing is a serious problem worldwide that
affects patients with various wound types, resulting from burns, traumatic
injuries, and diabetes. Despite the wide range of clinically available skin
substitutes and the different therapeutic alternatives, delayed healing and
scarring are often observed.
Recent Advances: Stem cells have arisen as powerful tools to improve skin
wound healing, due to features such as effective secretome, self-renewal, low
immunogenicity, and differentiation capacity. They represent potentially
readily available biological material that can particularly target distinct
wound-healing phases. In this context, mesenchymal stem cells have been
shown to promote cell migration, angiogenesis, and a possible regenerative
rather than fibrotic microenvironment at the wound site, mainly through
paracrine signaling with the surrounding cells/tissues.
Critical Issues: Despite the current insights, there are still major hurdles to be
overcome to achieve effective therapeutic effects. Limited engraftment and
survival at the wound site are still major concerns, and alternative approaches
to maximize stem cell potential are a major demand.
Future Directions: This review emphasizes two main strategies that have been
explored in this context. These comprise the exploration of hypoxic conditions
to modulate stem cell secretome, and the use of adipose tissue stromal vascular
fraction as a source of multiple cells, including stem cells and factors requiring
minimal manipulation. Nonetheless, the attainment of these approaches to
target successfully skin regeneration will be only evident after a significant
number of in vivo works in relevant pre-clinical models.
SCOPE AND SIGNIFICANCE
From a physiological perspec-
tive, effective skin wound healing
still represents a major concern for
global healthcare, as the currently
available skin substitutes and alter-
native therapeutics lead to unsatis-
factory results. This problematic
affects a wide range of patients with
various wound types resulting from
burns, traumatic injuries, and dia-
betes, where delayed healing and
scarring is a reality. In the past few
years, new insights into the wound-
healing process triggered the devel-
opment of more sophisticated strategies
that take advantage of specific per-
formers such as artificial extracellular
matrix (ECM)-like matrices, growth
factors, and primarily stem cells.
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TRANSLATIONAL RELEVANCE
Endogenous stem cells are vital players in the
well-coordinated cell-signaling cascades of wound
healing. From a therapeutic perspective, their
mobilization to the wound site has been suggested;
however, insights into their mechanism of action
are particularly difficult to attain. This has been
hampering clinically relevant outcomes, thus sup-
porting the exploitation of the therapeutic action of
exogenous stem cells. Whether these can act as
building blocks and/or potent secretome units is
deeply dependent on the cell source and on the
administration strategies. Both effects have been
shown to significantly impact wound healing, tar-
geting wound re-epithelialization, hair follicle (HF)
formation, and neovascularization.
CLINICAL RELEVANCE
Despite all the pre-clinical studies using exoge-
nous stem cells in a wound-healing context, transla-
tion into clinical trials is fairly recent. Themajority of
these focus on the use of bone marrow mesenchymal
stem cells (BM-MSCs) mostly to treat chronic
wounds. Alternatively, adipose stem cells (ASCs)
potential to treat burn wounds and diabetic foot/ve-
nous ulcers is currently being evaluated, addressing
variables such as cell number, administration mode,
andwound area. The knowledge acquired from these
trials is expected to lead the development of hybrid
constructs as ‘‘engineered regenerative platforms’’ to
actively encourage skin wound regeneration.
Stem cell involvement in wound-healing
phases
Wound healing is a complex dynamic response to
a physical trauma that comprises three overlapping
phases: inflammatory, proliferative, and remodel-
ing, extensively reviewed elsewhere1,2 (Box 1 for a
short overview of the main events). Their progres-
sion depends on a well-coordinated interplay of cell-
signaling events at the wound site and surrounding
tissues,2 in which endogenous stem cells are vital
players. These include HF bulge3–5 and dermal
sheath stem cells (DSCs),6 as well as mesenchymal
stem cells (MSCs) such as BM-MSCs7–9 and specu-
lativelyASCs,10 as very little is known in terms of its
endogenous role during wound healing. These cells
are located within distinct skin niches that are di-
vided mainly in epidermal and dermal niches.11
During both embryonic development and adult
homeostasis, epidermis and HF are distinct com-
partments formed by independent stem cell popu-
lations. HF, in particular, does not contribute to
interfollicular epidermis maintenance.3 However,
several authors revealed3–5 that after wounding,
HF bulge stem cells rapidly migrate toward the
interfollicular epidermis, generating short-lived
transient-amplifying cells that promote re-
epithelialization. Contrarily, DSCs surrounding
HF units ensure dermal papilla cell maintenance
and are involved in dermal repair by acquiring a
myofibroblastic phenotype.6 Despite the compart-
mentalized structure of skin, paracrine signaling
and cell–matrix communication are determinant to
modulate an efficient wound-healing response.12
Details on the internal mechanisms of action
within skin stem cell niches in a wound-healing
scenario were recently reviewed elsewhere,11–14
and they are not the focus of this review.
In this context, the mechanism of action of en-
dogenous stem cells outside the niche is particu-
larly difficult to understand. The disclosure of their
contribution in skin wound healing has been
hampered by the use of rodent models, mechanis-
tically different fromhumans, aswell as by the lack
of more sophisticated cell-tracking methodologies.
Moreover, the role of BM is controversial due to its
complex set of phenotypes and location, far from the
cutaneous wound site.9 Nonetheless, it is known
that BM-MSCs contribution to cutaneous wound
healing is substantially greater than the previously
recognized sub-population CD45+ , which is com-
posed by BM hematopoietic cells and antigen-
presenting fibroblasts.15 Additional evidence showed
that the contribution of BM-MSCs goes beyond early
inflammation, contrary to what was initially be-
lieved.16 These cells are maintained in the newly
formed dermis playing a substantial role in the
formation of new connective tissue through the
production of collagen I and III.7,15 More recently,
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further indications related to MSCs recruitment
from bone marrow to participate in wound healing
were demonstrated based on fetal microchimer-
ism.9 However, the role of other endogenous MSCs
in skin wound healing remains unknown. There-
fore, despite the indications provided by exogenous
application of ASCs on the regulation of blood ves-
sels formation through a crosstalk with endothelial
cells,10 studies that address its endogenous role for
skin hemostasis/healing are still missing.
Despite this limited knowledge, local stem cell
mobilization17,18 has been proposed as an answer
to the low engraftment rate of transplanted exog-
enous stem cells.19 Nonetheless, it is important to
highlight that these mechanisms have been stud-
ied in rodents and that the translational settings
toward humans might represent a long leap for a
clinical situation. Thus, themost followedapproach
for exploiting the therapeutic action of stem cells in
the wound healing has been the application of ex-
ogenousMSCs at thewound site and their potential
has been reviewed by several authors.14,20,21 They
can regulate specific events that occur along the
different phases of the wound-healing cascade,
as reviewed by Maxson et al.22 and summarized in
Fig. 1,23–30 opening distinct possibilities toward an
effective healing.
Stem cells as building blocks and secretome
units (771/8796)
Building blocks
Autologous skin substitute application in large
full-thickness wounds/burns is hampered by the
scarcity of biological material.31 To counter this,
different MSCs have started being used to replace
dermal fibroblasts (DFbs).32–34 Tonsil-derived
MSCs in a collagen-based dermal-epidermal con-
struct promoted epidermal stratification, cornifica-
tion, and pigmentation comparable to human
dermal fibroblasts (hDFbs), after transplantation in
immunocompromised rats.32 A similar outcomewas
found when the same cells were incorporated in a
decellularized dermis and transplanted into a laser
injury in humanized skin graft cultures.33However,
unlike ASCs,35 few studies detail the isolation pro-
cedures and expansion potential of tonsil-derived
MSCs, hindering, for now, their positioning as a
valid stem cell source. Epidermal-like cells and ad-
ipocytes generated from human adipose stem cells
(hASCs) obtained from the debridement of burned
Figure 1. Schematic overview of stem cell potential in the wound-healing scenario, along with their different mechanisms of action and potential outcome to
target different stages, such as inflammation, proliferation, and remodeling. IL-10, interleukin 10; TNF-a, tumor necrosis factor alpha; INFc, interferon gamma;
VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; KGF,
keratinocyte growth factor; HGF, hepatocyte growth factor; TGF-b, transforming growth factor beta. To see this illustration in color, the reader is referred to the
web version of this article at www.liebertpub.com/wound
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patient’s wounds34 were used to recreate the epider-
mal and hypodermal layers of a skin analogue where
the hDFbs of the dermal-like layer are replaced by
hASCs. Still, in vivo data are needed to validate
such constructs for cutaneous wound healing.
The works described earlier32–34 represent the
few stem cell-based alternatives to three-dimensional
(3D) organized dermo-epidermal substitutes,
highlighting the question whether it is necessary
to recreate a 3D substitute with the classical or-
ganization of the skin tissue to improve wound
healing. Considering the different number of
works using stem cells either injected at the wound
borders15,36 or randomly incorporated within bio-
material-based matrices,37–42 there is skepticism
regarding the need for 3D organization. None-
theless, this discrepancy can be correlated with the
limitations of MSC differentiation toward epithe-
lial and endothelial lineages,43 as well as to the
deficient purity/stability of epidermal stem cells
cultures.43 Stem cells from distinct sources, in-
cluding MSCs, have shown a strong effect in
HF formation.37,39,44,45 In our recently published
work,37 the enhanced HF formation appears to be
associated with keratinocyte growth factor (KGF)
overexpression resulting from a direct interaction
between resident keratinocytes (KCs) and trans-
planted hASCs cell sheet constructs. MSCs mech-
anisms that improve HF formation are, however,
still elusive.45 The identification of transplanted
MSCs in the neoepidermis27,42,46 has been sup-
porting the hypothesis of transdifferentiation into
epidermal cells. However, despite the set of in vitro
studies,47–49 this hypothesis is still poorly explored.
Transdifferentiation of MSCs into endothelial cells
after transplantation into cutaneous wounds is
also supported by few works showing mouse27,40
and human BM-MSCs-derived endothelial cell in-
tegration in the neo-vasculature. Interestingly,
these findings were also associated to a pericytic
phenotype of undifferentiated transplanted cells
also described by others45 and in accordance to the
reports that associate MSCs with perivascular ni-
ches and close/common origin with pericytes.50,51
Despite being able to act as building blocks, stem
cells rich secretome (discussed in the next section
‘‘Secretome units’’) appears to be the major tool to
modulate functional regeneration (Fig. 2).
Figure 2. Schematic perspective of stem cells as powerful tools in skin wound-healing improvement. Special highlight provided on their contribution as
building blocks and as potent secretome units at different responses levels. To see this illustration in color, the reader is referred to the web version of this
article at www.liebertpub.com/wound
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Secretome units
MSCs secretome has been analyzed to assess
stem cell mechanisms of action during the wound-
healing process. BM-MSCs52 and hASCs53 secre-
tome is immunosuppressant, modulating secretion
of factors such as interleukin (IL)-6/10 and tumor
necrosis factor alpha, as well as dendritic cell
functions. Curiously, BM-MSCs-conditioned me-
dium (CM) improved macrophage recruitment by
potentiating secretion of macrophage inflammatory
protein-1alpha/beta and erythropoietin.26 BM-
MSCs,26,54 hASCs,55 and umbilical cord mesenchy-
mal stem cells56 were also shown to release KGF,
fibroblast growth factor 2, and epidermal growth
factor. These promoted KCs migration in vivo, signif-
icantly influencing wound re-epithelialization.26,55,56
Likewise, the impact on wound angiogenesis/
vascularization at the wound site was also associ-
ated to vascular endothelial growth factor (VEGF)
secreted by mouse bone marrow mesenchymal
stem cells26 and hASCs.55 Other important regu-
lators of angiogenesis, namely angiogenin, VEGF-
A, and leptin,were also identified inhASCs, human
bone marrow mesenchymal stem cells, DSCs, and
dermal papilla cells (DPCs) secretome.54 While
angiogenin and VEGF-A secretion levels were
comparable within MSCs populations, DSCs and
DPCs released a significantly higher amount of
leptin. These angiogenic features were confirmed
in excisional26,57 and chronic wounds58 healing,
and they can be maximized by playing with the
oxygen concentration, as discussed in section ‘‘Hy-
poxia.’’ MSCs secretome can further act in the re-
modeling phase of cutaneous wound healing.
hASCs-CM is shown to promote the synthesis of
collagen I by DFbs,55,59,60 thus influencing wound
closure. This effect on DFbs was also observed
when human amniotic fluid MSCs-CM61,62 was
administrated in a mouse excisional wound, sug-
gesting their action via the transforming growth
factor beta (TGF-b)/SMAD2 pathway.62
Overall, these data demonstrate thatMSCs from
different sources have a potent secretome that is
capable of influencing different cells involved in the
wound-healing process, modulating their activa-
tion, migration, and proliferation.
Clinical placement
Clinical cases and trials
Despite all pre-clinical wound-healing studies,
translation of stem cell-based strategies in the
clinical settings is still reduced. Most of the clinical
trials/case studies comprise the use of BM and ad-
ipose tissue (AT) MSCs, to treat various wound
types, namely chronic wounds as recently revised
by Maxson et al.22 BM-MSCs, still considered
the gold standard for several applications, have
a history of successful healing of chronic wound
ulcerations,63,64 despite reported poor cellular en-
graftment. Therefore, new delivery strategies such
as the use of a fibrin spray are currently under
trial (NCT01751282). Alternatively, three different
Table 1. Key registered clinical trials/case studies of stem cell-based strategies for skin wound healing
Cell type Design Wound type Time frame Status/outcome Reference
Allogeneic BM-MSCs Injection: test of four different doses Second-degree burns
( < 20% TBSA)
No less than
52 weeks
Not yet recruiting NCT02104713a
Autologous BM-MSCs Forty injections of CD34+ cells Chronic critical limb ischemia,
diabetic foot
&17 weeks Therapy resulted in
79% limb salvage
NCT01232673a,36
Autologous BM-MSCs BM-MSCs in fibrin spray Non-healing 24 weeks Ongoing NCT01751282a
hASCs Multiple injections within and
periphery of the wound
Diabetic foot venous/pressure
ulcer
&10 weeks Recruiting NCT02092870a
hASCs Injection (3–8 · 106cells) and
incorporation in PRP matrix
Burns Not defined Ongoing 2012-001596-36b
hASCs Injection and spraying
(4.5· 106 cells)
Burns Not defined Ongoing 2009-016365-29c
SVF Injection Venous ulcers Not defined Not yet recruiting d
Autologous lipoaspirate Injection Diabetic/venous stasis wounds 52 weeks Unknown NCT00815217a









Recalcitrant vascular leg ulcers — Healing and complete closure 67
aIdentifier on US clinical trials website: http://clinicaltrials.gov/results for: stem+ cells+wounds.
bIdentifier on EU clinical trials website: http://clinicaltrialsregister.eu/results for: stem + cells+wounds.
cIdentifier on EU clinical trials website: http://clinicaltrialsregister.eu/results for: burn+mesenchymal stem cells.
dAustralian Clinical trials website: http://australianclinicaltrials.gov.au/.
BM-MSCs, bone marrow mesenchymal stem cells; TBSA, total body surface area; hASCs, human adipose stem cells; PRP, platelet-rich plasma; SVF, stromal
vascular fraction.
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registered clinical trials (Table 1) using hASCs to
treat burn wounds diabetic foot/venous ulcers are
being undertaken. Variables such as cell number
(NCT02092870), administration mode, including in-
corporation in platelet-rich plasma (2012-001596-36)
or spraying (2009-016365-29) versus injection, and site
of administration (NCT02092870)arebeingaddressed.
In a different perspective, other tissues/fractions
such as lipoaspirate and stromal vascular fraction
(SVF) that fit ‘‘minimal manipulation’’ criteria,
possibly with the rationale of particularly tackling
the lack of vasculature of venous ulcers, are being
tested (Box 1). In the same context, autologous scalp
HF grafts were directly transplanted into chronic
leg ulcers65 as healing units. Although yielding
promising results, limitations such as sample size,
absence of stratification in thewhole ulcer area, and
difficult follow-up due to fibrotic healing in some
patients, among others, were also identified.65
Interestingly, with the exception of BM-MSCs
delivered in fibrin, none of the most recent trials
has tested the combination of stem cells with bio-
material-based matrices. Apart from an earlier
trial that confirmed that autologous epidermal
equivalents engineered from outer root sheath
KCs (EpiDex) were safe and as effective as a
standardmesh graft in the treatment of recalcitrant
vascular leg ulcers,66 new skin analogues have not
reached clinical trials/case studies. However, arti-
ficial dermis with non-cultured autologous hASCs
and exogenous basic fibroblast growth factor (bFGF)
showed a high degree of success in the healing of
patients who suffered chronic radiation injuries.67
Overview of regulatory aspects
for clinical application
Stem cell-based products (apart some excep-
tions) are advanced therapy medicinal products
(ATMPs). These products imply ‘‘substantial ma-
nipulation’’ of tissues/cells, resulting in biological/
physiological function alteration.68 Cell products
with substantial or minimal manipulation are
distinguished by their regulatory systems. In vitro
cultivation of isolated cells represents substantial
manipulation, while the simple isolation of BM
mononuclear cells or SVF for an autologous ap-
proach enters the minimal manipulation category.
Regulatory requirements for these minimally ma-
nipulated products are similar to the ones for blood
banking products. This allows their preparation in
suitable transfusion or blood banking facilities.69
The ATMP regulation has been differently
managed worldwide; the EU and the United States
have implemented new systems for the regulation
of ATMPs that intend to merge, as much as possi-
ble, the regulatory requirements worldwide.70 In
the EU, the European Medicines Agency (EMA)
established a Committee for Advanced Therapies
(CAT) (in accordance to 1394/2007). The CAT has
the responsibility to analyze each ATMP applica-
tion submitted to EMA. The approval process also
requires the Committee for Medicinal Products for
Human Use feedback, whose decision is subse-
quently formalized by the European Commission
that binds all EU member states. In the United
States, applications are directed to the Food and
Drug Administration (FDA), the Office of Cellular,
Tissue, and Gene Therapies, and the Center for
Biologics Evaluation and Research; the review pro-
cess is conducted. Nonetheless, FDA has very much
adopted a case-by-case analysis of ATMPswith little
product ‘‘class’’ guidance to instruct compliance.
Maximization of stem cell potential
in wound healing
Despite all the hype on stem cells’ therapeutic
application for cutaneous wound healing, it is clear
that there is still significant room for improvements.
A new trend of the field has been following strate-
gies that can target mechanistic features of a skin
wound-healing microenvironment to maximize the
performance of stem cell-based approaches.
Hypoxia
In most of the human tissues, the oxygen (O2)
concentration that cells sense is significantly lower
than the atmospheric concentration, or normoxia
(20–21%, v/v), and it varies from 14% in highly
perfused tissues to 1% or less in the bonemarrow.71
Moreover, it is widely known that awounded tissue
is hypoxic due to the disruption of the blood vessels
and increased O2 consumption by the local cells.
72
Because ‘‘hypoxia’’ denotes a state where the O2 con-
centration to which a cell is subjected is lower than
thatat the cell native site orniche, it is a relative term.
Under the scope of this review, hypoxia refers to O2
concentration lower than the atmospheric one.
The O2 concentration is an integral part of the
stem cells’ niche71; BM-MSC, in particular, are
subjected to physiologic O2 concentrations between
1% and 3%.73 hASCs can face from 5% to 9%, but
some controversy regarding these values can be
found.74 Cells respond to O2 variations mainly
through the action of the hypoxia-inducible factor
(HIF)-1a.75,76 This highly conserved protein is de-
graded at atmospheric O2 concentrations
77 but
stable in hypoxic conditions, promoting the acti-
vation of target genes76,77 such as the angiogene-
sis- and the wound healing-related genes VEGF,
platelet-derived growth factor, TGF-b3, TGF-b1,
stromal cell-derived factor 1, and bFGF.75,78–83
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Despite the limited attention given to hypoxia
culture, an increasingnumber ofworksdemonstrate
that MSCs cultured under low O2 concentrations
have improved proliferation, clonogenicity, sur-
vival, and, notably, an enhanced secretome.
Hypoxia and wound healing. As referred in
section ‘‘Stem cells as building blocks and secre-
tome units (771/8796),’’, the major effect of stem
cells on skin healing has been associated to para-
crine signaling either directly or through their CM.
Thus, considering the impact of hypoxic conditions
in the nature of their secretome, it is likely that
their healing potential can be modulated under
those conditions. Chen et al.84 demonstrated that
hypoxic culture (2% O2) increases the expression
and secretion of bFGF, VEGF-A, and IL-6/8 in
mouse BM-MSCs, subsequently inducing prolifer-
ation andmigration of KCs, fibroblasts, endothelial
cells, and monocytes. This was also confirmed
in vivo after topical application of CM from hyp-
oxia-cultured BM-MSC in full-thickness excisional
wounds. In comparison to the use of CM from BM-
MSC cultured in normoxia, increased cell prolifera-
tion, neovascularization, as well as recruitment of
inflammatorymacrophages were observed. Increased
amounts of VEGF and bFGF in the CM of BM-MSC
cultured in hypoxiawere suggested to stimulate those
processes that will, ultimately, lead to enhanced skin
wound healing, although increased skin contraction
was also observed. While the involvement of VEGF
and bFGFwas similarly reported by Lee et al.85 using
CM of hASC cultured in hypoxic conditions (2% O2),
contrarily to what is stated by the authors, the effect
of neutralizing antibodies toVEGFandbFGFwasnot
reflected in the reduced wound area, and it was most
likely directly correlatedwith rodent skin contraction.
Interestingly, Frazier et al.86 analyzed the secretome
of hASCs cultured in hypoxia (5% O2) and observed
that low oxygen conditions may favor a fibrosis-
inhibiting, regeneration-promoting immunoregula-
tory role of hASCs inwoundhealing. In addition, the
use of a splinted wound imprinting control region
mousemodel, where the effect of wound contraction
in wound closure is eliminated,87 confirmed en-
hanced wound closure in animals treated with CM
of amniotic fluid-derived MSC (AF-MSCs) cultured
in hypoxia (1% O2) versus normoxia. CM of hypoxic
AF-MSCs CM contained elevated levels of VEGF
and TGF-b1 that induced hDFb migration in vitro.
This effect was reversed by the inhibition of TGF-b/
SMAD2 and PI3K/AKT pathways, suggesting that
wound-healing enhancement by AF-MSC hypoxia
CM happens, at least partially, via increased fibro-
blast recruitment and migration.
Overall, these works show how culture in hyp-
oxia can alter the MSC secretion patterns, likely to
have a paracrine effect on other cells and tissues
and impact the wound-healing process at different
stages. Hypoxia culture seems to be able to modu-
late inflammatory cell recruitment due to strong
secretion of immunomodulatory molecules such as
programed death ligand-1 and indoleamine 2,3-
dioxygenase,74 which will positively impact the
inflammatory phase of wound healing. Further-
more, increased secretion of VEGF and bFGF in
the hypoxic CM strongly suggests that the prolif-
erative wound-healing stage is affected by the
consequent increase in neo-angiogenesis by para-
crine signaling75,83 independently of the MSC
source. In opposition, the fibrosis-inhibiting sig-
naling might be dependent on both the O2 concen-
tration and the cell type, as a balance between
TGF-b1 and TGF-b3 is needed to achieve skin re-
generation rather than fibrosis and scarring (Fig.
3). However, to effectively harness this potential
of hypoxic-cultured stem cells, appropriate ways
to deliver cells to the wound site will have to be
developed. As shown in Table 1, there is a multi-
tude of strategies to deliver cells to the wound site,
ranging from injection to spraying or incorpora-
tion in a matrix. An incorrect strategy may not
translate the full potential of the cells. Therefore,
for each particular clinical setting, specific ap-
proaches must be defined to allow hypoxic-
cultured cells to maintain a favorable secretome
that results in improved healing or regeneration.
AT stromal vascular fraction. As described in
section ‘‘Overview of regulatory aspects,’’ despite
the attractiveness of hASCs for cutaneous heal-
ing,88 their use is associated with complex regula-
tory issues.68 In opposition, the use of SVF, a
heterogeneous mixture of 30–40% of ASCs and
endothelial cells, smooth muscle cells, pericytes,
fibroblasts, mast cells, and preadipocytes,89 enters
the ‘‘minimal manipulation’’ category, facilitating
clinical applications. The SVF unique composition
has been posed as beneficial to enhance the ASCs
regenerative potential, offering unique benefits in
cutaneous wound-healing applications.55,90 How-
ever, few clinical studies directly compare the ad-
ministration of cultured hASCs versus SVF and
additional data are still needed to reinforce the
current pre-clinical findings.
Current data show not only an effect of SVF on
collagen synthesis91 but also its strong angiogenic
potential.92,93 Very recently, Klar et al. suggested
that SVF possesses similar percentages of stromal
and endothelial cells, demonstrating that when in-
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corporated in 3D fibrin or collagen, SVF cells were
capable of de novo formation of microvascular net-
works, causing a rapid anastomosis with the host
vasculature and a sustained epidermal coverage.92
Moreover, when applied to burn wounds, increased
VEGF production and reduced inflammation was
observed.93 Likewise, in a scenario of diabetic
wounds, VEGF and bFGF expression was also in-
creased,94 accelerating the wound-healing process.
The several clinical studies using SVF to treat
several conditions of very distinct diseases re-
viewed elsewhere95,96 suggest that this stromal cell
fraction is safe and can be efficiently transplanted
in either an autologous or allogeneic manner.
However, as mentioned earlier, to our knowledge
only one trial is addressing the effectiveness of
autologous SVF under the scope of skin wound
healing in the treatment of venous ulcers.
FUTURE TRENDS
A new era in skin wound healing and regenera-
tion has risen in the past few years having stem
cells as central players. MSCs from bone marrow,
AT, AF, and umbilical cord matrix are among the
most explored. Their role is being discussed from
two intimately connected viewpoints: as building
blocks of the newly formed tissue due to their
(trans)differentiation ability and as potent secre-
tory units that can modulate the wound-healing
cell-signaling pathways. However, while transdif-
ferentiation mechanisms are poorly dissected, the
interest in MSCs secretome has been increasingly
rising. The spatiotemporal regulation of MSCs se-
cretome in the context of the different wound types
is, nevertheless, not achieved.
This uncertainty, as well as the reduced control
of the artificial hybrid microenvironments that are
being proposed, is greatly hampering the transla-
tion of stem cell-based strategies. Moreover, pre-
clinical validation using closer to human models
comprises a crucial step to support this translation.
The mouse skin full-thickness wound model is the
most used animal model, which, regardless of its
contribution and convenience, presents limitations
resulting from healing dissimilarities between
humans and rodents.97While in rodents the wound
closure occurs mainly via contraction, human skin
is tethered to subcutaneous tissues and wounds
heal by granulation tissue formation and re-epi-
Figure 3. Overview of strategies to maximize stem cell application/potential in the wound-healing context. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/wound
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thelialization. Due to the anatomic simi-
larities with the human skin as well as to
the identical mechanisms of healing, the
porcine model has been described as the
most suitable pre-clinical model in the
cutaneous wound context.98
Advances in material science opened up
the possibility of specifically tailoring a mi-
croenvironment to modulate cell behav-
ior,99namelyby incorporatingcell-adhesion
motifs,100 cell-signaling elements,101–104
and genetic encoding sequences.105–107
However, the sophistication of the designed
matrices is still not satisfactory. Likewise,
theunderstanding/control of biomechanical
mechanisms at the wound site through
mechanically tailored materials, minimiz-
ing scar tissue formation, has been under-
explored.108 Thus, the sustainedknowledge
acquired from the studies on the wound-
healing processes/events is expected to lead
the development of hybrid constructs as
‘‘engineered regenerative platforms’’ to ac-
tively encourage skin wound regeneration.
Sophisticated techniques that allow com-
bining stem cells with a maximized poten-
tial, within a matrix capable of mimicking
different aspects of the natural ECM, will certainly
have a significant impact. In this context, 3D biofab-
rication appears as a breakthrough technology in the
field of tissue engineering that offers advantages such
as the automated creation of hybrid structures that
differently combine living and non-livingmaterials in
a pre-defined 3D micro-organization.108–110 Biofabri-
cation strategies for skin regeneration/repair are
limited to the creation of skin grafts consisting of lay-
ered fibroblasts and KCs embedded in collagen,111,112
and more recently AF-MSCs within fibrin-
collagen.113 So far, major limitations have been
associated to the materials’ features that have to
comply not only with the fabrication requirements
but also with cellular phenotypic demands. But
ultimately, the design of engineered regenerative
platforms in which the placement of different cel-
lular units is within a specific microenvironment,
potentially biofunctional and mechanically ad-
justed, will lead the path to regenerate skin with
compartments, such as HF and other appendages.
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DSC¼ dermal sheath stem cell
EGF¼ epidermal growth factor
EMA¼ European Medicines Agency
FDA¼ Food and Drug Administration
hASC¼ human adipose stem cell
HF¼ hair follicle
HGF¼ hepatocyte growth factor




KGF¼ keratinocyte growth factor
MSC¼mesenchymal stem cell
PDGF¼ platelet-derived growth factor
PRP¼ platelet-rich plasma
SVF¼ stromal vascular fraction
TBSA¼ total body surface area
TGF-b¼ transforming growth factor beta
TNF-a¼ tumor necrosis factor alpha
VEGF¼ vascular endothelial growth factor
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